Alfavision Overseas (India) Limited (ALFAVIO.BO)
INR 14.4
(0.84%)
INR 14.4
(0.84%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 31.27 Million INR | -94.66% |
| 2022 | 585.82 Million INR | -67.74% |
| 2021 | 1.81 Billion INR | 1.38% |
| 2020 | 1.79 Billion INR | 14.09% |
| 2019 | 1.56 Billion INR | 34.8% |
| 2018 | 1.16 Billion INR | 18.12% |
| 2017 | 985.92 Million INR | 211.63% |
| 2016 | 316.37 Million INR | 0.19% |
| 2015 | 315.78 Million INR | -34.37% |
| 2014 | 481.15 Million INR | 25.73% |
| 2013 | 382.67 Million INR | 51.58% |
| 2012 | 252.46 Million INR | 340.59% |
| 2011 | 57.3 Million INR | 55.53% |
| 2010 | 36.84 Million INR | -38.77% |
| 2009 | 60.16 Million INR | 17.29% |
| 2008 | 51.29 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 9.69 Million INR | 820.99% |
| 2023 Q4 | 1.05 Million INR | -91.36% |
| 2023 Q3 | 12.18 Million INR | 35.51% |
| 2023 Q2 | 8.98 Million INR | -0.66% |
| 2023 Q1 | 9.04 Million INR | 147.53% |
| 2023 FY | 31.27 Million INR | -94.66% |
| 2022 Q2 | 71.9 Million INR | -68.27% |
| 2022 Q3 | 12.19 Million INR | -83.05% |
| 2022 Q4 | -19.04 Million INR | -256.18% |
| 2022 Q1 | 226.63 Million INR | -66.9% |
| 2022 FY | 585.82 Million INR | -67.74% |
| 2021 Q4 | 684.78 Million INR | 17.42% |
| 2021 Q1 | 10.57 Million INR | -98.13% |
| 2021 Q3 | 583.19 Million INR | 8.57% |
| 2021 Q2 | 537.17 Million INR | 4980.16% |
| 2021 FY | 1.81 Billion INR | 1.38% |
| 2020 Q2 | 486.21 Million INR | 88.19% |
| 2020 FY | 1.79 Billion INR | 14.09% |
| 2020 Q1 | 258.35 Million INR | -33.11% |
| 2020 Q3 | 482.13 Million INR | -0.84% |
| 2020 Q4 | 564.28 Million INR | 17.04% |
| 2019 FY | 1.56 Billion INR | 34.8% |
| 2019 Q1 | 354 Million INR | -7.98% |
| 2019 Q2 | 595.91 Million INR | 68.34% |
| 2019 Q3 | 234.77 Million INR | -60.6% |
| 2019 Q4 | 386.24 Million INR | 64.52% |
| 2018 Q1 | 276.27 Million INR | -7.45% |
| 2018 FY | 1.16 Billion INR | 18.12% |
| 2018 Q4 | 384.71 Million INR | 79.35% |
| 2018 Q3 | 214.5 Million INR | 38.87% |
| 2018 Q2 | 154.45 Million INR | -44.09% |
| 2017 Q2 | 2.88 Million INR | -91.13% |
| 2017 FY | 985.92 Million INR | 211.63% |
| 2017 Q1 | 32.45 Million INR | -89.64% |
| 2017 Q3 | 351.31 Million INR | 12098.58% |
| 2017 Q4 | 298.49 Million INR | -15.04% |
| 2016 Q4 | 313.28 Million INR | 19419.31% |
| 2016 Q3 | 1.6 Million INR | 179.13% |
| 2016 FY | 316.37 Million INR | 0.19% |
| 2016 Q1 | 1.57 Million INR | 96.25% |
| 2016 Q2 | 575 Thousand INR | -63.38% |
| 2015 Q4 | 800 Thousand INR | -97.98% |
| 2015 FY | 315.78 Million INR | -34.37% |
| 2015 Q3 | 39.55 Million INR | -64.67% |
| 2015 Q2 | 111.95 Million INR | -27.67% |
| 2015 Q1 | 154.78 Million INR | 30.05% |
| 2014 Q3 | 117.7 Million INR | -18.72% |
| 2014 FY | 481.15 Million INR | 25.73% |
| 2014 Q1 | 99.19 Million INR | 142.66% |
| 2014 Q2 | 144.81 Million INR | 45.99% |
| 2014 Q4 | 119.01 Million INR | 1.11% |
| 2013 Q4 | 40.87 Million INR | -62.52% |
| 2013 FY | 382.67 Million INR | 51.58% |
| 2013 Q1 | 92.31 Million INR | 41.01% |
| 2013 Q2 | 140.07 Million INR | 51.74% |
| 2013 Q3 | 109.07 Million INR | -22.13% |
| 2012 Q1 | 67.25 Million INR | 23.28% |
| 2012 Q2 | 34.54 Million INR | -48.63% |
| 2012 FY | 252.46 Million INR | 340.59% |
| 2012 Q3 | 84.52 Million INR | 144.67% |
| 2012 Q4 | 65.46 Million INR | -22.55% |
| 2011 FY | 57.3 Million INR | 55.53% |
| 2011 Q3 | - INR | 0.0% |
| 2011 Q4 | 54.55 Million INR | 0.0% |
| 2010 FY | 36.84 Million INR | -38.77% |
| 2010 Q4 | 827 Thousand INR | 0.0% |
| 2009 Q4 | 28.94 Million INR | 0.0% |
| 2009 FY | 60.16 Million INR | 17.29% |
| 2008 FY | 51.29 Million INR | 0.0% |
| 2008 Q4 | 17.41 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biocon Limited | 147.55 Billion INR | 99.979% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | 99.561% |
| Concord Biotech Limited | 10.16 Billion INR | 99.692% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | 99.88% |
| FERMENTA BIOTECH LIMITED | 3.35 Billion INR | 99.068% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.65 Million INR | -1794.472% |
| Lyka Labs Limited | 1.05 Billion INR | 97.025% |
| Panacea Biotec Limited | 5.51 Billion INR | 99.433% |
| SAMSRITA LABS LIMITED | - INR | -Infinity% |
| Servoteach Industries Limited | - INR | -Infinity% |
| SMS Lifesciences India Limited | 3.05 Billion INR | 98.978% |
| Supriya Lifescience Limited | 5.7 Billion INR | 99.452% |
| Syngene International Limited | 34.88 Billion INR | 99.91% |
| TAKE Solutions Limited | 656.08 Million INR | 95.233% |
| Titan Biotech Limited | 1.64 Billion INR | 98.094% |
| Transgene Biotek Limited | 2.34 Million INR | -1231.332% |
| Vanta Bioscience Limited | 97.22 Million INR | 67.836% |